|
|
|
|
Science Sparks @ ACTREC
|
 24 November 2025 |
Vol. No. 14 ; Issue No. 710 |
|
|
Publications
|
|
1. Gupta SD, Mishra GA, Pimple SA, Kulkarni VY, Patil AS, Shaikh HKA, Majmudar PV (2025). Tobacco use among Taxi Drivers in Mumbai, India: Prevalence and predictors. Indian Journal of Cancer. 62(3):388-394.
2. Kulkarni VY, Mishra GA, Pimple SA, Singal AM, Patil AS, Majmudar PV, Shaikh HA (2025). Tobacco abuse among public transport bus employees in Mumbai, India: A randomized control trial. Indian Journal of Cancer. 62(3):395-401.
3. Sinukumar S, Kazi M, Jumle N, Kumar L, Damodaran D, Sajna PV, Shuba C, Trivedi M, Chachhodwala T, Chandran H, Prabhu A, Shankar D, Bhatt A (2025). Stromal Tumor infiltrating lymphocytes (sTILs) as a prognostic biomarker in ovarian cancer after neoadjuvant chemotherapy. European Journal of Surgical Oncology.
4. Chilukuri S, Sundar SC, Subramani V, Arjunan M, Raveendran V, Kamath R, Meena L, Guruvaiah A, Phurailatpam R, Selvaraj R, Chaudhari L, Kumaar V, Jain N, Tiwari M, Halsana P, Sharma D, Maitre P, Murthy V (2025). Pre-PROTO-PRIME study: Stereotactic body proton therapy to the prostate and pelvic nodes for high-risk and node-positive prostate cancer — feasibility, acute toxicity and dosimetric insights. Clinical and Translational Radiation Oncology.
|
|
|
|
|
Interesting Reads
|
|
Kumari N, Wright SC, Witham CM, Monserrat L, Palafox M, Richard JL, Costa C, Elkabets M, Agostino M, Klemm T, Eccles M, Garnham A, Wu T, Nilsson JA, Walz N, Venugopal V, Cerra A, Vasilevski N, Bridgeman S, Bassi S, Saei A, Helal M, Neundorf P, Riedel A, Rosenfeldt M, Gill J, Pahor N, Hartmann O, Chung J, Sidhu SS, Moderau N, Jha S, Rodon J, Diefenbacher ME, Komander D, Serra V, Eichhorn PJA (2025). USP10/GSK3β-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer. Journal of Clinical Investigation. 135(22):e180927.
|
|
|
Video of the Week
|
|
| Nuclear Medicine Beyond RAI |
|
| |
|
|
| |
|
|
Upcoming Events
|
| |
|
MicroScope 2025
|
|
November 29, 2025
|
|
At Homi Bhabha Cancer Hospital & Research Centre, New Chandigarh
|
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Do You Know?
In 1997, FDA approved Rituxan (rituximab), the first monoclonal antibody, to treat non-Hodgkin’s lymphoma.
|
|
|
|
Cancer News
|
| |
|
St. Jude India ChildCare Centres Inaugurates India's Largest Childhood Cancer Sanctuary in Kharghar.
|
|
business wire, 22/11/2025
|
|
St. Jude India ChildCare Centres, in partnership with Tata Memorial Centre’s ACTREC, today inaugurated its largest ‘home away from home’ facility ,a 12-storey, 234-unit complex in Kharghar, Navi Mumbai , in the presence of Dr. Sudeep Gupta, Director, Tata Memorial Centre, along with other senior doctors...
...
|
| |
|
Blocking a single protein forces cancer cells to self-destruct
|
|
Sciencedaily, 20/11/2025
|
|
Researchers uncovered a powerful weakness in lung cancer by shutting down a protein that helps tumors survive stress. When this protein, FSP1, was blocked, lung tumors in mice shrank dramatically, with many cancer cells essentially triggering their own self-destruct mode...
|
|
|
|
|
| |
|
|
|
A microRNA cocktail to weaken brain tumors
|
|
Eurekalert, 20/11/2025
|
|
The research team focused on miRNAs, a type of non-coding RNA involved in gene regulation and in the key biological mechanisms that govern cell behavior, stimulating or inhibiting their growth. In particular, the researchers studied miRNAs involved in the differentiation of stem cells...
|
|
|
|
|
|
|
|
|
2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
